Hikma Pharmaceuticals Plc Share Buyback Programme (7817C)
February 25 2022 - 2:00AM
UK Regulatory
TIDMHIK
RNS Number : 7817C
Hikma Pharmaceuticals Plc
25 February 2022
Hikma Pharmaceuticals PLC
Share Buyback Programme
London, 25 February 2022 - As previously announced on 24
February 2022 in its preliminary audited results for the year ended
31 December 2021, Hikma Pharmaceuticals PLC ("Hikma") will launch a
buyback programme of up to $300 million to be executed during 2022
(the "Buyback Programme").
Hikma announces today that it has instructed Citigroup Global
Markets Limited ("Citi") to purchase Hikma's ordinary shares of 10
pence each ("Ordinary Shares") for an aggregate purchase price of
up to $150 million, pursuant to the Buyback Programme (the "Initial
Tranche"). Citi will act as riskless principal for the simultaneous
on-sale of such shares to Hikma and will make its trading decisions
concerning the timing of the purchases of Ordinary Shares
independently of Hikma. Purchases of the Ordinary Shares under the
Initial Tranche will commence on 25 February 2022 and end no later
than 25 June 2022 and will be carried out on the London Stock
Exchange and/or on BATS and/or on Chi-X trading venues.
Hikma expects to announce a second tranche to complete the
Buyback Programme in due course.
The purpose of the Buyback Programme is to reduce the share
capital of Hikma. To the extent permitted by law, all Ordinary
Shares purchased under the Buyback Programme will be cancelled.
Any acquisitions under the Initial Tranche will be carried out
within certain pre-set parameters, and in accordance with Hikma's
general authority to repurchase Ordinary Shares as granted at
Hikma's Annual General Meeting on 23 April 2021, pursuant to which
the maximum number of Ordinary Shares to be bought back by Hikma
may not exceed 24,333,210 Ordinary Shares.
Any acquisitions will be made in accordance with the EU Market
Abuse Regulation (596/2014) as it forms part of UK domestic law by
virtue of the European Union (Withdrawal) Act 2018 and Chapter 12
of the Listing Rules. The market will be notified in accordance
with those rules if and when purchases are made.
Enquiries
Susan Ringdal
EVP, Strategic Planning and Global +44 (0)20 7399 2760 / +44 (0)7776
Affairs 477050
Guy Featherstone +44 (0)20 3892 4389 / +44 (0)7795
Senior Investor Relations Manager 896738
Layan Kalisse +44 (0)20 7399 2788 / +44 (0)7970
Investor Relations Analyst 709912
About Hikma
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the United States (US), the
Middle East and North Africa (MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,700 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com .
(LEI:549300BNS685UXH4JI75)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSESFALEESEDE
(END) Dow Jones Newswires
February 25, 2022 02:00 ET (07:00 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024